1. Pharmacogenetics of warfarin dosing
Pharmacogenetics of warfarin dosing. Warfarin is metabolized by CYP2C9 to inactive metabolites and exerts its anticoagulant effect partly via inhibition of VKORC1 (vitamin K epoxide hydrolase), an enzyme necessary for reduction of inactive to active vitamin K. Common polymorphisms in both genes, CYP2C9 and VKORC1, impact on warfarin pharmacokinetics and pharmacodynamics, respectively, to affect the population mean therapeutic doses of warfarin necessary to maintain the desired degree of anticoagulation (often measured by the international normalized ratio [INR] blood test) and minimize the risk of too little anticoagulation (thrombosis) or too much anticoagulation (bleeding). See also Figure 30–6 and Table 30–2.
Source: Pharmacogenetics, Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e
Citation: Hilal-Dandan R, Brunton LL. Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e; 2016 Available at: Accessed: October 04, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved